Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 204

1.

Overcoming platinum-acquired resistance in ovarian cancer patient-derived xenografts.

Ricci F, Brunelli L, Affatato R, Chilà R, Verza M, Indraccolo S, Falcetta F, Fratelli M, Fruscio R, Pastorelli R, Damia G.

Ther Adv Med Oncol. 2019 Jun 24;11:1758835919839543. doi: 10.1177/1758835919839543. eCollection 2019.

2.

DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas.

Restelli V, Lupi M, Chilà R, Vagni M, Tarantelli C, Spriano F, Gaudio E, Bertoni F, Damia G, Carrassa L.

Mol Cancer Ther. 2019 Jul;18(7):1255-1264. doi: 10.1158/1535-7163.MCT-18-0919. Epub 2019 May 7.

PMID:
31064869
3.

Platinum Resistance in Ovarian Cancer: Role of DNA Repair.

Damia G, Broggini M.

Cancers (Basel). 2019 Jan 20;11(1). pii: E119. doi: 10.3390/cancers11010119. Review.

4.

Platinum sensitivity and DNA repair in a recently established panel of patient-derived ovarian carcinoma xenografts.

Guffanti F, Fratelli M, Ganzinelli M, Bolis M, Ricci F, Bizzaro F, Chilà R, Sina FP, Fruscio R, Lupia M, Cavallaro U, Cappelletti MR, Generali D, Giavazzi R, Damia G.

Oncotarget. 2018 May 15;9(37):24707-24717. doi: 10.18632/oncotarget.25185. eCollection 2018 May 15.

5.

Recent Insights into Mucinous Ovarian Carcinoma.

Ricci F, Affatato R, Carrassa L, Damia G.

Int J Mol Sci. 2018 May 24;19(6). pii: E1569. doi: 10.3390/ijms19061569. Review.

6.

Combining Ibrutinib with Chk1 Inhibitors Synergistically Targets Mantle Cell Lymphoma Cell Lines.

Restelli V, Lupi M, Vagni M, Chilà R, Bertoni F, Damia G, Carrassa L.

Target Oncol. 2018 Apr;13(2):235-245. doi: 10.1007/s11523-018-0553-6.

PMID:
29441438
7.

A High-throughput Screening of a Chemical Compound Library in Ovarian Cancer Stem Cells.

Ricci F, Carrassa L, Christodoulou MS, Passarella D, Michel B, Benhida R, Martinet N, Hunyadi A, Ioannou E, Roussis V, Musso L, Dallavalle S, Silvestri R, Westwood N, Mori M, Ingallina C, Botta B, Kavetsou E, Detsi A, Majer Z, Hudecz F, Bosze S, Kaminska B, Hansen TV, Bertrand P, Athanassopoulos CM, Damia G.

Comb Chem High Throughput Screen. 2018;21(1):50-56. doi: 10.2174/1386207321666180124093406.

PMID:
29366408
8.

DNA damage response inhibitors: Mechanisms and potential applications in cancer therapy.

Carrassa L, Damia G.

Cancer Treat Rev. 2017 Nov;60:139-151. doi: 10.1016/j.ctrv.2017.08.013. Epub 2017 Sep 19. Review.

PMID:
28961555
9.

Heteronanoparticles by self-Assembly of Doxorubicin and Cyclopamine Conjugates.

Fumagalli G, Stella B, Pastushenko I, Ricci F, Christodoulou MS, Damia G, Mazza D, Arpicco S, Giannini C, Morosi L, Dosio F, Sotiropoulou PA, Passarella D.

ACS Med Chem Lett. 2017 Aug 1;8(9):953-957. doi: 10.1021/acsmedchemlett.7b00262. eCollection 2017 Sep 14.

10.

Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts.

Ricci F, Guffanti F, Damia G, Broggini M.

Mol Cancer. 2017 May 30;16(1):97. doi: 10.1186/s12943-017-0662-3.

11.

MAL gene overexpression as a marker of high-grade serous ovarian carcinoma stem-like cells that predicts chemoresistance and poor prognosis.

Zanotti L, Romani C, Tassone L, Todeschini P, Tassi RA, Bandiera E, Damia G, Ricci F, Ardighieri L, Calza S, Marchini S, Beltrame L, Tognon G, D'Incalci M, Pecorelli S, Sartori E, Odicino F, Ravaggi A, Bignotti E.

BMC Cancer. 2017 May 25;17(1):366. doi: 10.1186/s12885-017-3334-1.

12.

Multi-Chemotherapeutic Schedules Containing the pan-FGFR Inhibitor ARQ 087 are Safe and Show Antitumor Activity in Different Xenograft Models.

Chilà R, Hall G T, Abbadessa G, Broggini M, Damia G.

Transl Oncol. 2017 Apr;10(2):153-157. doi: 10.1016/j.tranon.2016.12.003. Epub 2017 Feb 3.

13.

Resistance to glucose starvation as metabolic trait of platinum-resistant human epithelial ovarian cancer cells.

Pastò A, Pagotto A, Pilotto G, De Paoli A, De Salvo GL, Baldoni A, Nicoletto MO, Ricci F, Damia G, Bellio C, Indraccolo S, Amadori A.

Oncotarget. 2017 Jan 24;8(4):6433-6445. doi: 10.18632/oncotarget.14118.

14.

Inhibition of CHK1 and WEE1 as a new therapeutic approach in diffuse large B cell lymphomas with MYC deregulation.

Restelli V, Vagni M, Arribas AJ, Bertoni F, Damia G, Carrassa L.

Br J Haematol. 2018 Apr;181(1):129-133. doi: 10.1111/bjh.14506. Epub 2016 Dec 26. No abstract available.

PMID:
28025833
15.

In Vitro and In Vivo Activity of Lucitanib in FGFR1/2 Amplified or Mutated Cancer Models.

Guffanti F, Chilà R, Bello E, Zucchetti M, Zangarini M, Ceriani L, Ferrari M, Lupi M, Jacquet-Bescond A, Burbridge MF, Pierrat MJ, Damia G.

Neoplasia. 2017 Jan;19(1):35-42. doi: 10.1016/j.neo.2016.11.008. Epub 2016 Dec 15.

16.

The 5'UTR variant of ERCC5 fails to influence outcomes in ovarian and lung cancer patients undergoing treatment with platinum-based drugs.

Rulli E, Guffanti F, Caiola E, Ganzinelli M, Damia G, Garassino MC, Piva S, Ceppi L, Broggini M, Marabese M.

Sci Rep. 2016 Dec 14;6:39217. doi: 10.1038/srep39217.

17.

The impact of DNA damage response gene polymorphisms on therapeutic outcomes in late stage ovarian cancer.

Guffanti F, Fruscio R, Rulli E, Damia G.

Sci Rep. 2016 Dec 1;6:38142. doi: 10.1038/srep38142.

18.

Correction: Sunitinib prevents cachexia and prolongs survival of mice bearing renal cancer by restraining STAT3 and MuRF-1 activation in muscle.

Pretto F, Ghilardi C, Moschetta M, Bassi A, Rovida A, Scarlato V, Talamini L, Fiordaliso F, Bisighini C, Damia G, Bani MR, Piccirillo R, Giavazzi R.

Oncotarget. 2016 Jun 21;7(25):38973. doi: 10.18632/oncotarget.9971. No abstract available.

19.

Role and therapeutic potential of CDK12 in human cancers.

Chilà R, Guffanti F, Damia G.

Cancer Treat Rev. 2016 Nov;50:83-88. doi: 10.1016/j.ctrv.2016.09.003. Epub 2016 Sep 14. Review.

PMID:
27662623
20.

Can the response to a platinum-based therapy be predicted by the DNA repair status in non-small cell lung cancer?

Macerelli M, Ganzinelli M, Gouedard C, Broggini M, Garassino MC, Linardou H, Damia G, Wiesmüller L.

Cancer Treat Rev. 2016 Jul;48:8-19. doi: 10.1016/j.ctrv.2016.05.004. Epub 2016 May 24. Review.

PMID:
27262017
21.

4-(1,2-diarylbut-1-en-1-yl)isobutyranilide derivatives as inhibitors of topoisomerase II.

Christodoulou MS, Zarate M, Ricci F, Damia G, Pieraccini S, Dapiaggi F, Sironi M, Lo Presti L, García-Argáez AN, Dalla Via L, Passarella D.

Eur J Med Chem. 2016 Aug 8;118:79-89. doi: 10.1016/j.ejmech.2016.03.090. Epub 2016 Apr 11.

PMID:
27128175
22.

Patient-derived ovarian cancer xenografts re-growing after a cisplatinum treatment are less responsive to a second drug re-challenge: a new experimental setting to study response to therapy.

Ricci F, Fratelli M, Guffanti F, Porcu L, Spriano F, Dell'Anna T, Fruscio R, Damia G.

Oncotarget. 2017 Jan 31;8(5):7441-7451. doi: 10.18632/oncotarget.7465.

23.

Characterization of MTAP Gene Expression in Breast Cancer Patients and Cell Lines.

de Oliveira SF, Ganzinelli M, Chilà R, Serino L, Maciel ME, Urban Cde A, de Lima RS, Cavalli IJ, Generali D, Broggini M, Damia G, Ribeiro EM.

PLoS One. 2016 Jan 11;11(1):e0145647. doi: 10.1371/journal.pone.0145647. eCollection 2016.

24.

Designing a broad-spectrum integrative approach for cancer prevention and treatment.

Block KI, Gyllenhaal C, Lowe L, Amedei A, Amin ARMR, Amin A, Aquilano K, Arbiser J, Arreola A, Arzumanyan A, Ashraf SS, Azmi AS, Benencia F, Bhakta D, Bilsland A, Bishayee A, Blain SW, Block PB, Boosani CS, Carey TE, Carnero A, Carotenuto M, Casey SC, Chakrabarti M, Chaturvedi R, Chen GZ, Chen H, Chen S, Chen YC, Choi BK, Ciriolo MR, Coley HM, Collins AR, Connell M, Crawford S, Curran CS, Dabrosin C, Damia G, Dasgupta S, DeBerardinis RJ, Decker WK, Dhawan P, Diehl AME, Dong JT, Dou QP, Drew JE, Elkord E, El-Rayes B, Feitelson MA, Felsher DW, Ferguson LR, Fimognari C, Firestone GL, Frezza C, Fujii H, Fuster MM, Generali D, Georgakilas AG, Gieseler F, Gilbertson M, Green MF, Grue B, Guha G, Halicka D, Helferich WG, Heneberg P, Hentosh P, Hirschey MD, Hofseth LJ, Holcombe RF, Honoki K, Hsu HY, Huang GS, Jensen LD, Jiang WG, Jones LW, Karpowicz PA, Keith WN, Kerkar SP, Khan GN, Khatami M, Ko YH, Kucuk O, Kulathinal RJ, Kumar NB, Kwon BS, Le A, Lea MA, Lee HY, Lichtor T, Lin LT, Locasale JW, Lokeshwar BL, Longo VD, Lyssiotis CA, MacKenzie KL, Malhotra M, Marino M, Martinez-Chantar ML, Matheu A, Maxwell C, McDonnell E, Meeker AK, Mehrmohamadi M, Mehta K, Michelotti GA, Mohammad RM, Mohammed SI, Morre DJ, Muralidhar V, Muqbil I, Murphy MP, Nagaraju GP, Nahta R, Niccolai E, Nowsheen S, Panis C, Pantano F, Parslow VR, Pawelec G, Pedersen PL, Poore B, Poudyal D, Prakash S, Prince M, Raffaghello L, Rathmell JC, Rathmell WK, Ray SK, Reichrath J, Rezazadeh S, Ribatti D, Ricciardiello L, Robey RB, Rodier F, Rupasinghe HPV, Russo GL, Ryan EP, Samadi AK, Sanchez-Garcia I, Sanders AJ, Santini D, Sarkar M, Sasada T, Saxena NK, Shackelford RE, Shantha Kumara HMC, Sharma D, Shin DM, Sidransky D, Siegelin MD, Signori E, Singh N, Sivanand S, Sliva D, Smythe C, Spagnuolo C, Stafforini DM, Stagg J, Subbarayan PR, Sundin T, Talib WH, Thompson SK, Tran PT, Ungefroren H, Vander Heiden MG, Venkateswaran V, Vinay DS, Vlachostergios PJ, Wang Z, Wellen KE, Whelan RL, Yang ES, Yang H, Yang X, Yaswen P, Yedjou C, Yin X, Zhu J, Zollo M.

Semin Cancer Biol. 2015 Dec;35 Suppl:S276-S304. doi: 10.1016/j.semcancer.2015.09.007. Review.

25.

Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736.

Restelli V, Chilà R, Lupi M, Rinaldi A, Kwee I, Bertoni F, Damia G, Carrassa L.

Oncotarget. 2015 Nov 10;6(35):37229-40. doi: 10.18632/oncotarget.5954.

26.

Genomic instability in human cancer: Molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition.

Ferguson LR, Chen H, Collins AR, Connell M, Damia G, Dasgupta S, Malhotra M, Meeker AK, Amedei A, Amin A, Ashraf SS, Aquilano K, Azmi AS, Bhakta D, Bilsland A, Boosani CS, Chen S, Ciriolo MR, Fujii H, Guha G, Halicka D, Helferich WG, Keith WN, Mohammed SI, Niccolai E, Yang X, Honoki K, Parslow VR, Prakash S, Rezazadeh S, Shackelford RE, Sidransky D, Tran PT, Yang ES, Maxwell CA.

Semin Cancer Biol. 2015 Dec;35 Suppl:S5-S24. doi: 10.1016/j.semcancer.2015.03.005. Epub 2015 Apr 11. Review.

27.

Sunitinib prevents cachexia and prolongs survival of mice bearing renal cancer by restraining STAT3 and MuRF-1 activation in muscle.

Pretto F, Ghilardi C, Moschetta M, Bassi A, Rovida A, Scarlato V, Talamini L, Fiordaliso F, Bisighini C, Damia G, Bani MR, Piccirillo R, Giavazzi R.

Oncotarget. 2015 Feb 20;6(5):3043-54. Erratum in: Oncotarget. 2016 Jun 21;7(25):38973.

28.

Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma.

Chilà R, Basana A, Lupi M, Guffanti F, Gaudio E, Rinaldi A, Cascione L, Restelli V, Tarantelli C, Bertoni F, Damia G, Carrassa L.

Oncotarget. 2015 Feb 20;6(5):3394-408.

29.

Patient-derived ovarian tumor xenografts recapitulate human clinicopathology and genetic alterations.

Ricci F, Bizzaro F, Cesca M, Guffanti F, Ganzinelli M, Decio A, Ghilardi C, Perego P, Fruscio R, Buda A, Milani R, Ostano P, Chiorino G, Bani MR, Damia G, Giavazzi R.

Cancer Res. 2014 Dec 1;74(23):6980-90. doi: 10.1158/0008-5472.CAN-14-0274. Epub 2014 Oct 10.

30.

New class of squalene-based releasable nanoassemblies of paclitaxel, podophyllotoxin, camptothecin and epothilone A.

Borrelli S, Christodoulou MS, Ficarra I, Silvani A, Cappelletti G, Cartelli D, Damia G, Ricci F, Zucchetti M, Dosio F, Passarella D.

Eur J Med Chem. 2014 Oct 6;85:179-90. doi: 10.1016/j.ejmech.2014.07.035. Epub 2014 Jul 27.

PMID:
25084144
31.

Benzylidenetetralones, cyclic chalcone analogues, induce cell cycle arrest and apoptosis in HCT116 colorectal cancer cells.

Drutovic D, Chripkova M, Pilatova M, Kruzliak P, Perjesi P, Sarissky M, Lupi M, Damia G, Broggini M, Mojzis J.

Tumour Biol. 2014 Oct;35(10):9967-75. doi: 10.1007/s13277-014-2289-y. Epub 2014 Jul 10.

PMID:
25008568
32.

The pharmacological point of view of resistance to therapy in tumors.

Damia G, Garattini S.

Cancer Treat Rev. 2014 Sep;40(8):909-16. doi: 10.1016/j.ctrv.2014.05.008. Epub 2014 Jun 9. Review.

PMID:
24969326
33.

Successes and limitations of targeted cancer therapy in ovarian cancer.

Damia G, Sessa C.

Prog Tumor Res. 2014;41:89-97. doi: 10.1159/000355905. Epub 2014 Feb 17. Review.

PMID:
24727989
34.

HPLC-MS/MS method for quantitative determination of the novel dual inhibitor of FGF and VEGF receptors E-3810 in tumor tissues from xenograft mice and human biopsies.

Zangarini M, Ceriani L, Bello E, Damia G, Cereda R, Camboni MG, Zucchetti M.

J Mass Spectrom. 2014 Jan;49(1):19-26. doi: 10.1002/jms.3305.

PMID:
24446259
35.

Tumor shrinkage and improved quality of life in a heavily pretreated metastatic breast cancer patient treated with eribulin.

La Verde N, Piva S, Ganzinelli M, Farina G, Gherardi G, Girelli S, Bramati A, Del Re L, Damia G.

Future Oncol. 2013 Nov;9(11):1703-9. doi: 10.2217/fon.13.169.

PMID:
24156329
36.

Triple negative breast cancers have a reduced expression of DNA repair genes.

Ribeiro E, Ganzinelli M, Andreis D, Bertoni R, Giardini R, Fox SB, Broggini M, Bottini A, Zanoni V, Bazzola L, Foroni C, Generali D, Damia G.

PLoS One. 2013 Jun 25;8(6):e66243. doi: 10.1371/journal.pone.0066243. Print 2013.

37.

ALDH enzymatic activity and CD133 positivity and response to chemotherapy in ovarian cancer patients.

Ricci F, Bernasconi S, Porcu L, Erba E, Panini N, Fruscio R, Sina F, Torri V, Broggini M, Damia G.

Am J Cancer Res. 2013 Apr 3;3(2):221-9. Print 2013.

38.

Chk1-Mad2 interaction: a crosslink between the DNA damage checkpoint and the mitotic spindle checkpoint.

Chilà R, Celenza C, Lupi M, Damia G, Carrassa L.

Cell Cycle. 2013 Apr 1;12(7):1083-90. doi: 10.4161/cc.24090. Epub 2013 Mar 1.

39.

Revisiting ovarian cancer preclinical models: implications for a better management of the disease.

Ricci F, Broggini M, Damia G.

Cancer Treat Rev. 2013 Oct;39(6):561-8. doi: 10.1016/j.ctrv.2013.01.005. Epub 2013 Feb 19. Review.

PMID:
23434073
40.

Evaluation of safety and efficacy of tivantinib in the treatment of inoperable or recurrent non-small-cell lung cancer.

Broggini M, Garassino MC, Damia G.

Cancer Manag Res. 2013;5:15-20. doi: 10.2147/CMAR.S29995. Epub 2013 Jan 17.

41.

The tyrosine kinase inhibitor E-3810 combined with paclitaxel inhibits the growth of advanced-stage triple-negative breast cancer xenografts.

Bello E, Taraboletti G, Colella G, Zucchetti M, Forestieri D, Licandro SA, Berndt A, Richter P, D'Incalci M, Cavalletti E, Giavazzi R, Camboni G, Damia G.

Mol Cancer Ther. 2013 Feb;12(2):131-40. doi: 10.1158/1535-7163.MCT-12-0275-T. Epub 2012 Dec 27.

42.

Is PDGFR an important target for E-3810?

Damia G, Colella G, Camboni G, D'Incalci M.

J Cell Mol Med. 2012 Nov;16(11):2838-9. doi: 10.1111/j.1582-4934.2012.01601.x. No abstract available.

43.

Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo.

Carrassa L, Chilà R, Lupi M, Ricci F, Celenza C, Mazzoletti M, Broggini M, Damia G.

Cell Cycle. 2012 Jul 1;11(13):2507-17. doi: 10.4161/cc.20899. Epub 2012 Jul 1.

PMID:
22713237
44.

Ovarian carcinoma tumor-initiating cells have a mesenchymal phenotype.

Ricci F, Bernasconi S, Perego P, Ganzinelli M, Russo G, Bono F, Mangioni C, Fruscio R, Signorelli M, Broggini M, Damia G.

Cell Cycle. 2012 May 15;11(10):1966-76. doi: 10.4161/cc.20308. Epub 2012 May 15.

PMID:
22544328
45.

Epithelial-mesenchymal transition and breast cancer: role, molecular mechanisms and clinical impact.

Foroni C, Broggini M, Generali D, Damia G.

Cancer Treat Rev. 2012 Oct;38(6):689-97. doi: 10.1016/j.ctrv.2011.11.001. Epub 2011 Nov 26. Review.

PMID:
22118888
46.

International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010).

Berruti A, Generali D, Kaufmann M, Puztai L, Curigliano G, Aglietta M, Gianni L, Miller WR, Untch M, Sotiriou C, Daidone M, Conte P, Kennedy D, Damia G, Petronini P, Di Cosimo S, Bruzzi P, Dowsett M, Desmedt C, Mansel RE, Olivetti L, Tondini C, Sapino A, Fenaroli P, Tortora G, Thorne H, Bertolini F, Ferrozzi F, Danova M, Tagliabue E, de Azambuja E, Makris A, Tampellini M, Dontu G, Van't Veer L, Harris AL, Fox SB, Dogliotti L, Bottini A.

J Natl Cancer Inst Monogr. 2011;2011(43):147-51. doi: 10.1093/jncimonographs/lgr037.

PMID:
22043063
47.

New omics information for clinical trial utility in the primary setting.

Damia G, Broggini M, Marsoni S, Venturini S, Generali D.

J Natl Cancer Inst Monogr. 2011;2011(43):128-33. doi: 10.1093/jncimonographs/lgr032.

PMID:
22043059
48.

Characterization of a new trabectedin-resistant myxoid liposarcoma cell line that shows collateral sensitivity to methylating agents.

Uboldi S, Bernasconi S, Romano M, Marchini S, Fuso Nerini I, Damia G, Ganzinelli M, Marangon E, Sala F, Clivio L, Chiorino G, Di Giandomenico S, Rocchi M, Capozzi O, Margison GP, Watson AJ, Caccuri AM, Pastore A, Fossati A, Mantovani R, Grosso F, Tercero JC, Erba E, D'Incalci M.

Int J Cancer. 2012 Jul 1;131(1):59-69. doi: 10.1002/ijc.26340. Epub 2011 Aug 30.

49.

Unleashing Chk1 in cancer therapy.

Carrassa L, Damia G.

Cell Cycle. 2011 Jul 1;10(13):2121-8. Epub 2011 Jul 1. Review.

PMID:
21610326
50.

Expression of DNA repair genes in ovarian cancer samples: biological and clinical considerations.

Ganzinelli M, Mariani P, Cattaneo D, Fossati R, Fruscio R, Corso S, Ricci F, Broggini M, Damia G.

Eur J Cancer. 2011 May;47(7):1086-94. doi: 10.1016/j.ejca.2010.11.029. Epub 2011 Jan 7.

PMID:
21216588

Supplemental Content

Support Center